A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 31 May 2018
At a glance
- Drugs CNM Au8 (Primary)
- Indications Demyelinating disorders; Multiple sclerosis; Optic neuritis
- Focus Therapeutic Use
- Acronyms VISIONARY-MS
- 14 May 2018 Status changed from planning to not yet recruiting.
- 06 Feb 2018 New trial record
- 02 Feb 2018 According to the Clene Nanomedicine media release, this trial is set to begin in the second half of 2018.